Infliximab biosimilar (Merck & Co/Samsung Bioepis)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInfliximab biosimilar (Merck & Co/Samsung Bioepis)
Drug Alias NameInfliximabum (ABDA)英利昔单抗 (默克集团/Samsung Bioepis)infliximab biosimilar英夫利昔单抗 (默克集团/Samsung Bioepis)Renflexis +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisPsoriasisCrohn Disease +[7] 
Global Approved IndicationsPlaque psoriasisPsoriasisCrohn Disease +[7] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2016/05/26
Country/TerritoryBulgariaUnited StatesGermany +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSamsung Bioepis Co LtdMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesBiogen IncMerck & Co IncSamsung Bioepis Nl Bv +[5] 
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisCrohn Disease +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AB02
Related LinksN/A